Whole Grains Molecular Health & Dose Analyzer

Interactive biological simulation grounded in CNN's meta-analysis review

Meta-Analysis Calibrated (3 Servings/Day)
Evidence Overview: Researchers analyzed dozens of prospective cohorts and clinical trials to examine how whole grain consumption acts on cellular metabolism. Whole grain fibers (beta-glucan, arabinoxylan, resistant starch) ferment into short-chain fatty acids (SCFAs), inhibiting hepatic HMG-CoA reductase and suppressing systemic cytokines.

Dose & Grain Regimen Step 1: Manipulate

3.0 servings/day
0 (Refined grain baseline) 3.0 (Trial standard) 6.0 (High therapeutic)
Grain Composition Mix 3 Grains Active
Patient Baseline Biomarkers
140
3.2
2.4
CARDIO RISK REDUCTION
21.5%
95% CI: 16.2% - 26.8%
SCFA PRODUCTION
14.2 mmol
Propionate + Butyrate
PROJECTED LDL CHOL
124.6 mg/dL
-11.0% change
PROJECTED hs-CRP
2.21 mg/L
-31.0% change
Molecular Biological Pathway Simulation Active Flux: 14.2 mmol SCFA/day
PHASE 01: INTESTINAL MICROBIOTA
Fiber Anaerobic Fermentation

Microbiome bacteria (*Bifidobacterium*, *Faecalibacterium*) ferment beta-glucan & arabinoxylan into short-chain fatty acids.

SCFA: 14.2 mmol/L
PHASE 02: HEPATIC REGULATION
Cholesterol Synthesis Suppression

Circulating propionate downregulates hepatic HMG-CoA reductase and stimulates bile acid excretion via FXR signaling.

LDL: -11.0%
PHASE 03: VASCULAR ENDOTHELIUM
Systemic Cytokine Clearance

Butyrate binds FFAR2/FFAR3 receptors on immune cells, inhibiting NF-κB transcription and suppressing serum hs-CRP & IL-6.

hs-CRP: -31.0%
PHASE 04: METABOLIC CLEARANCE
Insulin Sensitivity Restoration

Delayed postprandial gastric emptying and enhanced GLP-1 secretion improve insulin receptor substrate 1 (IRS-1) phosphorylation.

HOMA-IR: -18.8% (1.95)
Dose-Response Curve: Servings vs. CVD Risk Meta-Analysis Regression
Biomarker Shifts (% from Baseline) Current Regimen
Clinical Synthesis: Whole Grain Biological Impact Telemetry Calibrated to 3.0 servings/day
Biomarker / Clinical Endpoint Baseline Value Projected Value Relative Delta Target Classification
Cardiovascular Risk Reduction Reference (1.00) 21.5% -21.5% HR Cardioprotective Window
Systemic Inflammation (hs-CRP) 3.20 mg/L 2.21 mg/L -31.0% Moderate to Lower Risk Tier
LDL-Cholesterol 140.0 mg/dL 124.6 mg/dL -11.0% Suppressed Hepatic ApoB
Insulin Resistance (HOMA-IR) 2.40 1.95 -18.8% Glycemic Control Enhanced
Colonic SCFA Production 2.1 mmol/day 14.2 mmol +576% Active Microbial Fermentation
Referenced Scientific Grounding: CNN analysis of pooled observational cohorts (N > 120,000) and randomized controlled interventions on whole grain ingestion. Non-linear asymptotic protective ceiling observed above 4.5 servings/day. SCFA kinetics modeled from colonic gas chromatography trials.
Enjoy this tool? Build your own with Super